drugset / Trial / NCT07014540
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
Phase 4
Not yet recruiting
45 enrolled
Beijing GoBroad Hospital
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of irinotecan liposome injection combined with 5-FU/LV in the treatment of advanced neuroendocrine carcinoma (NEC)
Timeline
- Start
- 2025-06-20
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 70 mg/m2 | Intravenous |
| Subject | LV | Unknown | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |